GLP-1 Receptor Agonist Global Market Opportunities and Strategies to 2035

This report describes and explains the GLP-1 receptor agonist market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global GLP-1 receptor agonist market reached a value of nearly $65.86 billion in 2025, having grown at a compound annual growth rate (CAGR) of 37% since 2020. The market is expected to grow from $65.86 billion in 2025 to $139.26 billion in 2030 at a rate of 16.2%. The market is then expected to grow at a CAGR of 15.5% from 2030 and reach $286.41 billion in 2035.

Growth in the historic period resulted from the growth of personalized and precision medicine, increased diagnosis rates of metabolic disorders, rising prevalence of diabetes and surge in real-world evidence supporting long-term weight loss. Factors that negatively affected growth in the historic period were high discontinuation rates due to GI side effects and rising competition from alternative therapies.

Going forward, the increased focus on preventive care, rise in obesity rates, growing awareness of cardiovascular and weight-loss benefits and expansion of insurance coverage for obesity treatments will drive the growth. Factors that could hinder the growth of the GLP-1 receptor agonist market in the future include misuse, off-label use, and non-medical consumption, high drug costs compared to standard diabetes or obesity therapy and impact of trade war and tariffs.

The GLP-1 receptor agonist market is segmented by drug class into liraglutide, semaglutide, tirzepatide, dulaglutide and other drugs. The semaglutide market was the largest segment of the GLP-1 receptor agonist market segmented by drug class, accounting for 51.9% or $34.18 billion of the total in 2025. Going forward, the tirzepatide segment is expected to be the fastest growing segment in the GLP-1 receptor agonist market segmented by drug class, at a CAGR of 17.8% during 2025-2030.

The GLP-1 receptor agonist market is segmented by route of administration into parenteral and oral. The parenteral market was the largest segment of the GLP-1 receptor agonist market segmented by route of administration, accounting for 81.2% or $53.49 billion of the total in 2025. Going forward, the oral segment is expected to be the fastest growing segment in the GLP-1 receptor agonist market segmented by route of administration, at a CAGR of 25.3% during 2025-2030.

The GLP-1 receptor agonist market is segmented by end users into hospitals, surgical clinics and other users. The hospitals market was the largest segment of the GLP-1 receptor agonist market segmented by end users, accounting for 55.1% or $36.26 billion of the total in 2025. Going forward, the hospitals segment is expected to be the fastest growing segment in the GLP-1 receptor agonist market segmented by end users, at a CAGR of 17.1% during 2025-2030.

North America was the largest region in the GLP-1 receptor agonist market, accounting for 72.63% or $47.83 billion of the total in 2025. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the GLP-1 receptor agonist market will be Africa and Middle East where growth will be at CAGRs of 33.25% and 29.92% respectively. These will be followed by Eastern Europe and South America where the markets are expected to grow at CAGRs of 26.44% and 26.42% respectively.

The global GLP-1 receptor agonist market is highly concentrated, with large players operating in the market. The top seven competitors in the market made up 93.89% of the total market in 2024. Novo Nordisk AS was the largest competitor with a 55.10% share of the market, followed by Eli Lilly Company with 38.51%, AstraZeneca Inc. with 0.11%, Sanofi SA with 0.09%, Glenmark Pharmaceuticals Limited with 0.04%, Teva Pharmaceutical Industries Ltd. with 0.03% and Amneal Pharmaceuticals with 0.01%.

The top opportunities in the GLP-1 receptor agonist markets segmented by drug class will arise in the semaglutide segment, which will gain $38.23 billion of global annual sales by 2030. The top opportunities in the GLP-1 receptor agonist markets segmented by route of administration will arise in the parenteral segment, which will gain $47.56 billion of global annual sales by 2030. The top opportunities in the GLP-1 receptor agonist markets segmented by end users will arise in the hospitals segment, which will gain $43.59 billion of global annual sales by 2030. The GLP-1 receptor agonist market size will gain the most in the USA at $36.44 billion.

Market-trend-based strategies for the GLP-1 receptor agonist market include focus on development of oral GLP-1 formulations designed to address rising global demand for more convenient, non-injectable metabolic therapies, integration of dual GLP-1/GIP agonist therapies designed to deliver greater weight-loss efficacy and broader metabolic benefits compared to traditional single-pathway treatments and launch of dual GLP-1/glucagon agonist therapies designed to target both metabolic dysfunction and liver disease progression in patients with obesity.

Player-adopted strategies in the GLP-1 receptor agonist market include focus on expanding business capabilities through innovation.

To take advantage of the opportunities, the analyst recommends the GLP-1 receptor agonist companies to focus on expanding oral and patient-centric GLP-1 therapies, focus on advancing dual GLP-1/GIP therapies for superior obesity outcomes, focus on developing dual GLP-1/glucagon agonists for metabolic liver disease, focus on expanding semaglutide and tirzepatide offerings to capture high-growth segments, focus on expanding oral glp-1 therapies to capture rapidly growing market demand, focus on wind power systems as the fastest-growing segment, focus on variable speed drives to capture high-growth opportunities, focus on expanding distribution channels across non-traditional care settings, focus on strategic pricing to enhance market access and competitiveness, focus on educating healthcare providers to drive adoption, focus on patient-centric awareness campaigns to expand engagement, focus on expanding GLP-1 access through other users channels.

This product will be delivered within 3-5 business days.